Predictive Therapeutics Press Release Archive

Predictive Technology Group, Inc.’s (PRED) Subsidiary Predictive Therapeutics Receives Favorable Ruling from the United States Patent and Trademark Office’s Patent Trial and Appeal Board on Spine Deformity Test and Bio-Implant

Decision may positively impact Company’s pipeline tests and companion treatment technologies

Salt Lake City, UT — (February 02, 2016) – Predictive Technology Group, Inc. (OTC PINK:PRED), a life sciences technology holding company, announced its subsidiary Predictive Therapeutics received a favorable ruling from the United States Patent and Trademark Office’s Patent Trial and Appeal Board (“PTAB”) on its spinal deformity molecular diagnostic tests and companion therapeutics (US Patent application 20150127105).

Mike Schramm, Predictive Therapeutics’ Director of Intellectual Property, said, “We are pleased that the Patent Trial and Appeal Board completely reversed the examiner and tacitly approved all twenty pending claims of the ‘105 application and we now look forward to a speedy allowance.  The claims of the ‘105 application build on previously issued US patents 8,123,787 and 8,641,738 to which ‘105 claims priority and further bolster PRED’s Intellectual Property position.”

Bradley Robinson, PRED’s CEO added, “PRED is excited to move forward with the release of the subsidiary’s, Predictive Therapeutics, spinal deformity tests and begin development work on the companion therapeutics. Predictive Therapeutics is committed to providing our surgeon customers with the highest quality predictive diagnostics and treatment solutions that can ultimately benefit their patients.”

The Company believes that this favorable PTAB decision will have an impact on the other diagnostic tests and companion product candidates that are in our R&D pipeline.

About Predictive Technology Group, Inc.

 Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about this release, contact, Mr. Rich Kaiser, YES INTERNATIONAL 757-306-6090, yes@yesinternational.com and/or www.predrx.com and/or www.predictivetechnologygroup.com.

 Forward-Looking Statements

 To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

 

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) MOVES CORPORATE OFFICES TO SALT LAKE CITY, UTAH

Salt Lake City, UT- Predictive Technology Group, Inc. (PRED.OTC), a life sciences technology holding Company, announces moving its Corporate office to Salt Lake City, Utah.

The Corporation’s new address is:

Predictive Technology Group, Inc. 

2749 Parleys Way, Suite 101,Salt Lake City, Utah 84109

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions.  PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about this release, contact Mr. Rich Kaiser, YES INTERNATIONAL, 757-306-6090 and/or yes@yesinternational.com, www.predictivetechnologygroup.com and/or www.predrx.com.

Forward-Looking Statements 
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) ANNOUNCES INITIAL MEMBERS OF FINANCIAL ADVISORY BOARD

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) ANNOUNCES INITIAL MEMBERS OF FINANCIAL ADVISORY BOARD

Salt Lake City, UT- Predictive Technology Group, Inc. (PRED.OTC), a life sciences technology holding Company, announces initial members of its “Financial Advisory Board.”

In conjunction with closing LifeCode Genetics, Inc. acquisition, Predictive Technology Group, Inc. has formed a “Financial Advisory Board.” These initial board members were the early investors/shareholders of LifeCode Genetics, Inc., who now own PRED shares post acquisition.

The three initial Financial Advisory Board members are as follows:

Dr. Gregory A. Prince – Pioneered the prevention of respiratory syncytial virus (RSV) disease in high-risk infants through the use of monoclonal antibody (SynagisÒ is currently marketed through a partnership between MedImmune and Abbvie); DDS and PhD (pathology) at UCLA; post-doctoral fellowship at the National Institutes of Health; CEO Virion Systems; National Advisory Councils, Johns Hopkins University School of Education, Utah Valley University, Dixie State University (chair); author of over 150 scientific publications in the field of infectious diseases.

Ronald Barhorst – Retired President and CEO of ING Financial Advisers, LLC, Systematized Benefits Administrators, Inc., and ING Investment Advisors, LLC. Mr. Barhorst served as a director of ING Life Insurance Holding Company, Inc. and as an officer of several other ING companies.  Mr. Barhorst currently serves as Chairman on the California State University Foundation Board of Governors.

Jonas Cedergren – Managing Director, JC Capital.  He was previously Managing Director, Head of European Equity Derivatives, and Head of Northern Europe, Barclays Capital, London, Managing Director and Head of Nordics, Credit Suisse, London and Vice President, Bankers Trust. Previous Board Member of Enter Card Europe.

Bradley Robinson, President, Predictive Technology Group, Inc., states, “The commitment and wealth of experience of the members of the ‘Financial Advisory Board’ will bring valued governance and guidance. As PRED moves forward with commercialization of its diagnostics and therapeutics, in its mission of revolutionizing patient care through novel gene-base companion diagnostics and therapeutics, these ‘Financial Advisory Board’ members will provide support and advice in PRED’s current and future business direction.”

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions.  PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about this release, contact Mr. Rich Kaiser, YES INTERNATIONAL, 757-306-6090 and/or yes@yesinternational.com, www.predictivetechnologygroup.com and/or www.predrx.com.

Forward-Looking Statements 
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.